Professor Allan Wailoo
BSc, MA, MSc, PhD
Population Health, School of Medicine and Population Health
Professor of Health Economics
Director of NICE Decision Support Unit [DSU]
Co-Director of the Policy Research Unit in Economic Methods of Evaluation in Health and Care Interventions [EEPRU]
+44 114 222 0729
Full contact details
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
- Profile
-
I joined ScHARR in 2000 having previously worked at the University of Leicester and was awarded a Personal Chair in 2012. I am Director of the NICE Decision Support Unit, and Co-Director of the Policy Research Unit in Economic Methods of Evaluation in Health & Care Interventions. I have Masters and PhD degrees in Economics and recently completed a Masters in Probability and Statistics at the University of Sheffield.
- Research interests
-
- Economic evaluation including alongside clinical trials and decision modelling
- Analysis of patient level data, particularly around health utilities
- Social values and decision making, including equity and procedural preferences
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods. Value in Health, 18(4), 425-431.
- Societal Preferences for Distributive Justice in the Allocation of Health Care Resources. Medical Decision Making, 35(1), 94-105.
- Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences.. Health Expect, 18(5), 1227-1240. View this article in WRRO
- Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.. Rheumatology (Oxford), 53(10), 1773-1777.
- A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes.. Med Decis Making, 34(7), 919-930.
- Modelling the relationship between the WOMAC Osteoarthritis Index and EQ-5D.. Health Qual Life Outcomes, 12, 37. View this article in WRRO
- The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.. Rheumatology (Oxford), 52(5), 944-950. View this article in WRRO
- Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.. Value Health, 15(3), 550-561.
- Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project.. Heart, 96(9), 668-672.
- Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.. Arthritis Rheum, 58(4), 939-946.
- Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.. Value Health, 11(2), 160-171.
All publications
Journal articles
- Does EQ-5D tell the whole story? Statistical methods for comparing the thematiccoverage of clinical and generic outcome measures, with application to breast cancer. Value in Health.
- Correction to: Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. BMC Cancer, 22(1).
- Convergent validity of EQ-5D with core outcomes in dementia: a systematic review. Health and Quality of Life Outcomes, 20(1). View this article in WRRO
- Protocol for the ORION trial (RadiO fRequency ablatION for haemorrhoids): a randomised controlled trial. Techniques in Coloproctology. View this article in WRRO
- Should we consider including a value for "Hope" as an additional benefit within health technology assessment?. Value in Health. View this article in WRRO
- A discrete choice experiment to elicit general population preferences around the factors influencing the choice to make clinical negligence claims. Value in Health. View this article in WRRO
- Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real-world data : opportunities and challenges. PharmacoEconomics. View this article in WRRO
- Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. Programme Grants for Applied Research, 9(8). View this article in WRRO
- An international comparison of EQ-5D-5L and EQ-5D-3L for use in cost-effectiveness analysis. Value in Health.
- A review of the psychometric performance of selected child and adolescent preference-based measures used to produce utilities for child and adolescent health. Value in Health. View this article in WRRO
- The clinical effectiveness of intensive management in moderate established rheumatoid arthritis : the titrate trial. Seminars in Arthritis and Rheumatism, 50(5), 1182-1190. View this article in WRRO
- OP0078 MAPPING FROM THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) TO EQ5D IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 79(Suppl 1), 52.1-53.
- A review of the methods used to generate utility values in NICE technology assessments for children and adolescents. Value in Health. View this article in WRRO
- The EQ-5D-5L value set for England: Findings of a quality assurance program. Value in Health. View this article in WRRO
- MRI in the diagnosis of fetal developmental brain abnormalities : the MERIDIAN diagnostic accuracy study. Health Technology Assessment, 23(49), 1-144. View this article in WRRO
- Identifying the need for good practices in health technology assessment: Summary of the ISPOR HTA council working group report on good practices in HTA. Value in Health, 22(1), 13-20. View this article in WRRO
- United Kingdom Catheter Study – Protocol Synopsis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 38(4), 314-314.
- Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping. Value in Health. View this article in WRRO
- The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals. PharmacoEconomics. View this article in WRRO
- Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma. Value in Health, 21(6), 748-757. View this article in WRRO
- Valuing health at the end of life: A review of stated preference studies in the social sciences literature. Social Science & Medicine, 204, 39-50. View this article in WRRO
- What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technology Assessment, 22(20). View this article in WRRO
- EQ-5D-5L versus EQ-5D-3L: The Impact on Cost-Effectiveness in the United Kingdom. Value in Health, 21(1), 49-56. View this article in WRRO
- Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. Trials, 18(1), 591-591. View this article in WRRO
- Use of MRI in the Diagnosis of Fetal Brain Abnormalities in Utero (MERIDIAN). Obstetric Anesthesia Digest, 37(4), 202-203.
- The clinical effectiveness and Cost-Effectiveness of Treat-To-Target strategies in rheumatoid arthritis: A systematic review and cost-effectiveness analysis. Health Technology Assessment, 21(71), 1-258. View this article in WRRO
- The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. PharmacoEconomics, 35(12), 1287-1296. View this article in WRRO
- United Kingdom Catheter Study- Protocol Synopsis. Peritoneal Dialysis International. View this article in WRRO
- Predicting responses in patients with rheumatoid arthritis to disease-modifying agents using baseline clinical data. Clinical and Experimental Rheumatology, 35(5), 810-815.
- How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework. Health Economics. View this article in WRRO
- The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. Journal of Rheumatology, 44(7), 973-980. View this article in WRRO
- Use of MRI in the Diagnosis of Fetal Brain Abnormalities in Utero (MERIDIAN). Obstetrical & Gynecological Survey, 72(6), 323-325.
- Change in diagnostic confidence brought about by using in utero MRI for fetal structural brain pathology: Analysis of the MERIDIAN cohort. Clinical Radiology. View this article in WRRO
- Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial. PharmacoEconomics Open. View this article in WRRO
- Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method. Statistical Methods in Medical Research, 26(2), 724-751.
- Mapping to Estimate Health-State Utility from Non–Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 20(1), 18-27. View this article in WRRO
- Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study. The Lancet, 389(10068), 538-546. View this article in WRRO
- The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technology Assessment, 20(90). View this article in WRRO
- The HubBle trial: Haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: A multicentre randomized controlled trial and health-economic evaluation. Health Technology Assessment, 20(88), 1-180. View this article in WRRO
- The Cost-Effectiveness of Antibiotic Prophylaxis for Patients at Risk of Infective Endocarditis. Circulation, 134(20), 1568-1578. View this article in WRRO
- Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 611-614.
- Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial. The Lancet, 388(10042), 356-364. View this article in WRRO
- Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 1-610. View this article in WRRO
- Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy, 2(2), 113-125. View this article in WRRO
- Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods. Value in Health, 18(4), 425-431.
- Valuing health at the end of life: A stated preference discrete choice experiment. Social Science & Medicine, 124, 48-56. View this article in WRRO
- Societal Preferences for Distributive Justice in the Allocation of Health Care Resources. Medical Decision Making, 35(1), 94-105.
- Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences.. Health Expect, 18(5), 1227-1240. View this article in WRRO
- Fitting Adjusted Limited Dependent Variable Mixture Models to EQ-5D. The Stata Journal: Promoting communications on statistics and Stata, 15(3), 737-750. View this article in WRRO
- Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.. Rheumatology (Oxford), 53(10), 1773-1777.
- Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.. Semin Arthritis Rheum, 44(2), 131-144. View this article in WRRO
- A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes.. Med Decis Making, 34(7), 919-930.
- The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open, 4. View this article in WRRO
- Valuing health at the end of life: an empirical study of public preferences.. Eur J Health Econ, 15(4), 389-399.
- Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.. Med Decis Making, 34(3), 387-402.
- Modelling the relationship between the WOMAC Osteoarthritis Index and EQ-5D.. Health Qual Life Outcomes, 12, 37. View this article in WRRO
- Variations in primary care prescribing: lessons to be learnt for GP commissioners.. Prim Health Care Res Dev, 15(1), 111-116.
- COMPARING THE VALUE OF DIFFERENT HTA DECISION MAKING PROCESS: EVALUATING THE EVALUATORS. VALUE IN HEALTH, 16(7), A489-A489.
- MODELLING THE RELATIONSHIP BETWEEN THE WO MAC OSTEOARTHRITIS INDEX AND EQ-5D. VALUE IN HEALTH, 16(7), A606-A606.
- Good practice guidelines for the use of statistical regression models in economic evaluations.. Pharmacoeconomics, 31(8), 643-652.
- The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.. Rheumatology (Oxford), 52(5), 944-950. View this article in WRRO
- A review of the psychometric performance of the EQ-5D in people with urinary incontinence.. Health Qual Life Outcomes, 11, 20. View this article in WRRO
- Estimating health state utility values for joint health conditions: a conceptual review and critique of the current evidence.. Med Decis Making, 33(2), 139-153.
- The HubBLe trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for haemorrhoids.. BMC Gastroenterol, 12, 153. View this article in WRRO
- Payers' views on treating-to-target in rheumatoid arthritis: an English perspective.. Clin Exp Rheumatol, 30(4 Suppl 73), S85-S90.
- Using health state utility values in models exploring the cost-effectiveness of health technologies.. Value Health, 15(6), 971-974.
- Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.. Value Health, 15(3), 550-561.
- The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.. Health Technol Assess, 16(21), 1-470.
- Valuing Health at the End of Life: An Exploratory Preference Elicitation Study.
- Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.. BMC Med Res Methodol, 11, 4. View this article in WRRO
- Improving call-to-balloon times for ST-elevation myocardial infarction. Journal of Paramedic Practice, 3(11), 625-631.
- MODELLING EQ-5D HEALTH STATE VALUES: DEVELOPING A LIMITED DEPENDENT VARIABLE, MIXTURE MODELING APPROACH. VALUE IN HEALTH, 14(7), A242-A242.
- A LITERATURE REVIEW OF METHODS USED TO ESTIMATE MEAN PREFERENCE-BASED UTILITIES FOR COMORBIDITIES USING PUBLISHED SUMMARY STATISTICS. VALUE IN HEALTH, 14(7), A425-A425.
- The Sheffield rheumatoid arthritis health economic model.. Rheumatology (Oxford), 50 Suppl 4, iv26-iv31.
- The cost-effectiveness of primary angioplasty. Heart, 97(2), 163-163.
- Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.. J Rheumatol, 38(8), 1593-1600.
- The cost-effectiveness of primary angioplasty reply. HEART, 97(2), 163-163.
- Demands for 'off-licence' access to trastuzumab (Herceptin): content analysis of UK newspaper articles.. Health Expect, 14(1), 38-47.
- The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis.. Rheumatology (Oxford), 49(12), 2313-2321. View this article in WRRO
- Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project.. Heart, 96(9), 668-672.
- The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.. Br J Cancer, 100(3), 436-441. View this article in WRRO
- Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected.. Pharmacoeconomics, 27(12), 983-989.
- Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply. RHEUMATOLOGY, 47(10), 1590-1590.
- Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.. Arthritis Rheum, 58(4), 939-946.
- The nature and impact of urinary incontinence experienced by patients receiving community nursing services: a cross-sectional cohort study.. Int J Nurs Stud, 45(3), 339-351.
- Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.. Value Health, 11(2), 160-171.
- Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.. Rheumatology (Oxford), 47(2), 119-120.
- Cost effectiveness of chest pain unit care in the NHS.. BMC Health Serv Res, 8, 174. View this article in WRRO
- It ain't what you do, it's the way that you do it: Characteristics of procedural justice and their importance in social decision-making. J ECON BEHAV ORGAN, 64(1), 157-170.
- Optimal algorithm for evaluating suspected DVT. J FAM PRACTICE, 55(9), 754-754.
- The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. HEALTH TECHNOL ASSES, 10(24), 1-+.
- Cluster randomized controlled trial of the effectiveness of audit and feedback and educational outreach on improving nursing practice and patient outcomes.. Med Care, 44(6), 542-551.
- How should we diagnose suspected deep-vein thrombosis?. QJM, 99(6), 377-388.
- Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.. Health technology assessment (Winchester, England), 10(15).
- The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age.. Vaccine, 24(7), 1035-1043.
- The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.. Health technology assessment (Winchester, England), 10(24).
- Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technology Assessment, 10(15). View this article in WRRO
- The nature of procedural preferences for health-care rationing decisions.. Soc Sci Med, 60(2), 223-236.
- Procedural justice in public health care resource allocation.. Appl Health Econ Health Policy, 4(2), 119-127.
- NICE clinical guidelines: Maybe health economists should participate in guideline development. BMJ, 329(7465), 571.1-571.1.
- Efficiency, equity, and NICE clinical guidelines. British Medical Journal, 328(7439), 536-537. View this article in WRRO
- View this article in WRRO NICE clinical guidelines [2] (multiple letters). British Medical Journal, 329(7465), 571-572.
- A systematic review of molecular and biological tumor markers in neuroblastoma.. Clin Cancer Res, 10(1 Pt 1), 4-12.
- Cost-effectiveness and value of information analyses of the use of antivirals for the treatment of influenza in healthy adults. VALUE HEALTH, 6(6), 755-755.
- NICE's citizen's council: what do we ask them, and how?. LANCET, 362(9387), 918-919.
- Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BRIT MED J, 326(7401), 1235-+.
- Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.. Health technology assessment (Winchester, England), 7(35).
- A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.. Health technology assessment (Winchester, England), 7(5), 1-162.
- Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment, 7(35).
- A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. Health Technology Assessment, 7(5).
- A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family.. Eur J Cancer, 39(1), 19-30.
- A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.. Health Technol Assess, 7(5), 1-162.
- Exploring the determinants of unhappiness for ethnic minority men in Britain. SCOT J POLIT ECON, 49(4), 445-466.
- Utilities versus rights to publicly provided goods: Arguments and evidence from health care rationing. ECONOMICA, 67(268), 543-577.
- View this article in WRRO Exploring the factors that drive clinical negligence claims: stated preferences of those who have experienced unintended harm. Patient: Patient-Centered Outcomes Research.
- Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study. PharmacoEconomics.
- View this article in WRRO Assessing the psychometric performance of EQ-5D-5L in dementia: a systematic review. Health and Quality of Life Outcomes.
- View this article in WRRO Should we consider including a value for ‘hope’ as an additional benefit within HTA?. Value in Health.
- Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods. Health Technology Assessment, 24(34), 1-68. View this article in WRRO
- The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation. Health Technology Assessment, 22(11), 1-204. View this article in WRRO
- A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technology Assessment, 10(20).
- Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. SN Comprehensive Clinical Medicine.
- Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. BMC Cancer.
- MEASURING QUALITY OF LIFE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS FOR ECONOMIC EVALUATION. RMD Open.
- A cost-effectiveness analysis of remdesivir for the treatment of hospitalised patients with COVID-19 in England and Wales. Value in Health.
- Exploring the issues of valuing child and adolescent health states using a mixed sample of adolescents and adults. PharmacoEconomics.
Chapters
- Health economics of rheumatoid arthritis, Oxford Textbook of Rheumatoid Arthritis (pp. 259-270). Oxford University Press
- Primary Angioplasty in Health Care Delivery, Clinical Guide to Primary Angioplasty (pp. 179-182). CRC Press
- Primary Angioplasty in Health Care Delivery: The Economics, CLINICAL GUIDE TO PRIMARY ANGIOPLASTY (pp. 179-182).
Conference proceedings papers
- Convergent validity of EQ-5D with core outcomes in dementia: a systematic review. QUALITY OF LIFE RESEARCH, Vol. 32(SUPPL 1) (pp S10-S10)
- Valuing health-related quality of life in children and adolescents: Who should we ask and how? A study protocol for consulting the public and experts in health valuation. QUALITY OF LIFE RESEARCH, Vol. 31 (pp S146-S146)
- ECONOMIC EVALUATION OF NEUTRALISING MONOCLONAL ANTIBODIES FOR THE TREATMENT OF COVID-19 POSITIVE PEOPLE IN THE COMMUNITY. VALUE IN HEALTH, Vol. 25(7) (pp S395-S395)
- Are child and adolescent-specific measures used to inform resource allocation decisions? A review of the methods used to generate utility values in NICE technology appraisals for children and adolescents. QUALITY OF LIFE RESEARCH, Vol. 28 (pp S110-S110)
- Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 1 December 2018.
- Haemorrhoidal Artery Ligation Procedure For The Treatment of Symptomatic Grade II–III Heamorrhoids: A Trial-Based And Long-Term Model-Based Economic Evaluation. Value in Health, Vol. 20(9) (pp A666-A666)
- ULTRASOUND COMPARED WITH BIOPSY IN THE DIAGNOSIS OF SUSPECTED GIANT CELL ARTERITIS. RHEUMATOLOGY, Vol. 55 (pp 37-37)
- INTERRATER AND INTRARATER ANALYSIS OF ULTRASOUND AND HISTOLOGICAL FINDINGS IN PATIENTS WITH SUSPECTED GIANT CELL ARTERITIS. RHEUMATOLOGY, Vol. 55 (pp 171-171)
- The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards. Value in Health, Vol. 17(7) (pp A380-A380)
- ADJUSTING FOR TREATMENT SWITCHING IN CLINICAL TRIALS WHEN ONLY SUMMARY DATA ARE AVAILABLE - AN EVALUATION OF POTENTIAL METHODS. VALUE IN HEALTH, Vol. 16(7) (pp A610-A611)
- A GUIDE TO ADJUSTING SURVIVAL TIME ESTIMATES TO ACCOUNT FOR TREATMENT SWITCHING IN RANDOMISED CONTROLLED TRIALS. VALUE IN HEALTH, Vol. 16(7) (pp A325-A325)
- COMMON TRAJECTORIES OF HAQ DISABILITY PROGRESSION OVER 15-YEARS IN THE EARLY RHEUMATOID ARTHRITIS STUDY AND THE NORFOLK ARTHRITIS REGISTER. ANNALS OF THE RHEUMATIC DISEASES, Vol. 71 (pp 508-508)
- METHODS FOR ESTIMATING SURVIVAL BENEFITS IN THE PRESENCE OF TREATMENT CROSSOVER: A SIMULATION STUDY. VALUE IN HEALTH, Vol. 15(7) (pp A462-A462)
- COMBINATION DMARDS FOR RHEUMATOID ARTHRITIS: A COST-EFFECTIVENESS ANALYSIS. RHEUMATOLOGY, Vol. 48 (pp I68-I69)
- Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. HEALTH ECONOMICS, Vol. 13(3) (pp 203-226)
Reports
- Health related quality of life in economic evaluations in dementia: state of play and reflections
- Scoping, assessing feasibility, preliminary research and prioritising projects for the outcome measurement and valuation
- A literature review of methods to measure and value benefits in cost-effectiveness analyses of interventions for patients with either a short life expectancy or receiving palliative care’
- Valuing child health: Exploring the use of a mixed sample of adolescents and adults to value child and adolescent health states
- Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available
- A review of the psychometric performance of paediatric preference-based measures used to generate utility values for children
- A review of the methods used to generate utility values in NICE technology appraisals for paediatrics
Scholarly editions
- Happy and healthy: a joint model of health and life satisfaction.
- A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence.
- Utilities vs. Rights to Publicly Provided Goods: Arguments and Evidence from Health-Care Rationing.
- Unhappiness and Involuntary Unemployment: The Case of Ethnic Minority Men in Britain.
Posters
- Safety of intravitreal bevacizumab as a monotherapy in ophthalmic conditions: systematic review. Health Technology Assessment International.
- A review of methods used to estimate mean preference-based utilities for comorbidities using published summary statistics.
- Estimating EQ-5D health states values for Rheumatoid Arthritis patients: a limited dependent variable, mixture modelling approach (2012).
Preprints
- Teaching activities
-
I lead the "Health Economics" module for the MSc Health Economics and Decision Modelling and teach on various other modules of the same course.
- Professional activities and memberships
-
- Director of the NICE Decision Support Unit
- Co-Director of the Policy Research Unit in Economic Methods of Evaluation in Health & Care Interventions